Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27461863 | 0.94 | PTPN11 (0.56) | PTPN11EGFRKCNH2 | |
| SCHEMBL30110987 | 0.90 | PTPN11 (0.64) | PTPN11 | |
| SCHEMBL24879212 | 0.90 | PTPN11 (0.64) | PTPN11 | |
| SCHEMBL30110905 | 0.87 | PTPN11 (0.48) | PTPN11EGFRKCNH2 | |
| SCHEMBL24879098 | 0.87 | PTPN11 (0.48) | PTPN11EGFRKCNH2 | |
| SCHEMBL24879241 | 0.86 | PTPN11 (0.50) | PTPN11KCNH2 | |
| SCHEMBL24878769 | 0.85 | PTPN11 (0.48) | PTPN11KCNH2 | |
| SCHEMBL24878775 | 0.85 | PTPN11 (0.44) | PTPN11EGFRKCNH2 | |
| SCHEMBL27454397 | 0.84 | PTPN11 (0.56) | PTPN11 | |
| SCHEMBL24879261 | 0.84 | PTPN11 (0.61) | PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | disclosed |
| EP-4368625-A1 | SHP2 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-05-15 | — | — | EP | disclosed |
| WO-2023282702-A1 | SHP2 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN2 | PTPN11 16/4885EGFR 806/4885KCNH2 4661/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | PTPN11 16/4885EGFR 806/4885KCNH2 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.